<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988779</url>
  </required_header>
  <id_info>
    <org_study_id>45566</org_study_id>
    <nct_id>NCT01988779</nct_id>
  </id_info>
  <brief_title>Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations</brief_title>
  <official_title>Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to treat patients with a diagnosis of chronic rhinosinusitis&#xD;
      (CRS) and a history of bilateral endoscopic sinus surgery during times of worsening symptoms&#xD;
      and signs of acute infection on nasal endoscopy with one of two treatments: (1) oral&#xD;
      antibiotics and twice daily intranasal saline irrigations or (2) oral placebo and twice daily&#xD;
      intranasal antibiotic irrigations. The two treatments will be compared to see if there is any&#xD;
      difference in patient outcomes. This will help guide treatment strategies for patients with&#xD;
      CRS in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 11, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Rhinosinusitis Disability Index (RSDI) Score</measure>
    <time_frame>Baseline and 14 days after treatment</time_frame>
    <description>The Rhinosinusitis Disability Index is a 30-item questionnaire completed by the patient or subject. Each item has a value of zero to four, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 120.&#xD;
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sino-nasal Outcome Test (SNOT-22) Score</measure>
    <time_frame>Baseline and 14 days after treatment</time_frame>
    <description>The Sino-nasal outcome test is a 22-item questionnaire completed by the patient or subject. Each item has a value of zero to five, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 110.&#xD;
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bilateral Endoscopy Findings Using POSE Score</measure>
    <time_frame>Baseline and 14 days after treatment</time_frame>
    <description>The Perioperative Sinus Endoscopy (POSE) instrument is a specific tool to endoscopically assess the sinus cavities of patients who have undergone endoscopic sinus surgery.&#xD;
Each POSE score has a minimum of 0 and a maximum of 16, with a higher score indicating a worse outcome.&#xD;
Here, the Left and Right POSE scores are summed and the difference between baseline and the 14 day after treatment is reported.&#xD;
The change in bilateral POSE score can in principle be -32 to +32, with increased scores indicating worse outcome and negative scores indicating improvement over the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-treatment Culture Negativity</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>Post-treatment culture negativity, defined as less than 1+ growth of organisms. A subject is counted '1' if both nares are free of bacterial growth, and '0' if growth is 1+ of more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the Total Bacterial Community</measure>
    <time_frame>Baseline and 14 days after treatment</time_frame>
    <description>The bacterial community was determined using a 16S rRNA quantitative PCR processed using Quantitative Insights into Microbial Ecology (QIIME) software, version 1.8 to yield the number of operational taxonomic units in each subject sample. The count has a minimum of zero with an increasing score indicating a larger number of distinct bacterial species.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral levofloxacin</intervention_name>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebulized levofloxacin</intervention_name>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (age â‰¥ 18).&#xD;
&#xD;
          2. Diagnosis of CRS.&#xD;
&#xD;
          3. Worsening sinonasal symptoms.&#xD;
&#xD;
          4. Previous bilateral endoscopic sinus surgery (ESS) (including maxillary antrostomy and&#xD;
             anterior ethmoidectomy).&#xD;
&#xD;
          5. English speaking.&#xD;
&#xD;
          6. Open sinuses (open middle meatus bilaterally; determined on endoscopy).&#xD;
&#xD;
          7. Positive sinonasal culture (1+ or greater) with sensitivity to one of the pre-chosen&#xD;
             antibiotic regimens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients &lt; 18 years of age.&#xD;
&#xD;
          2. Treatment with systemic or topical antibiotics within the last 1 month.&#xD;
&#xD;
          3. Pregnant women.&#xD;
&#xD;
          4. Non-English speaking persons.&#xD;
&#xD;
          5. Systemically ill at initial visit necessitating treatment prior to culture data.&#xD;
&#xD;
          6. Allergies to chosen susceptible antibiotics.&#xD;
&#xD;
          7. Sinonasal culture with less than 1+ growth.&#xD;
&#xD;
          8. Multiple organisms grown on culture that are not sensitive to a single antibiotic.&#xD;
&#xD;
          9. Patients with ciliary function disorders (cystic fibrosis, Kartagener's syndrome,&#xD;
             ciliary dyskinesia).&#xD;
&#xD;
         10. Patients with immunodeficiencies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Xing Man, MD, MPA, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Department of Otolaryngology Head and Neck Surgery</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <results_first_submitted>November 21, 2019</results_first_submitted>
  <results_first_submitted_qc>November 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2019</results_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Li-Xing Man</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01988779/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>8 participants screen failed before randomization to the intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
          <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
        </group>
        <group group_id="P2">
          <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
          <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
          <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
        </group>
        <group group_id="B2">
          <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
          <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Rhinosinusitis Disability Index (RSDI) Score</title>
        <description>The Rhinosinusitis Disability Index is a 30-item questionnaire completed by the patient or subject. Each item has a value of zero to four, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 120.&#xD;
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
        <time_frame>Baseline and 14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rhinosinusitis Disability Index (RSDI) Score</title>
          <description>The Rhinosinusitis Disability Index is a 30-item questionnaire completed by the patient or subject. Each item has a value of zero to four, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 120.&#xD;
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.000" spread="29.47"/>
                    <measurement group_id="O2" value="-14.82" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming that the non-inferiority limit of topical therapy is 20% of that for oral therapy.</non_inferiority_desc>
            <p_value>0.505</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sino-nasal Outcome Test (SNOT-22) Score</title>
        <description>The Sino-nasal outcome test is a 22-item questionnaire completed by the patient or subject. Each item has a value of zero to five, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 110.&#xD;
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
        <time_frame>Baseline and 14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sino-nasal Outcome Test (SNOT-22) Score</title>
          <description>The Sino-nasal outcome test is a 22-item questionnaire completed by the patient or subject. Each item has a value of zero to five, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 110.&#xD;
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.333" spread="33.02"/>
                    <measurement group_id="O2" value="-18.73" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bilateral Endoscopy Findings Using POSE Score</title>
        <description>The Perioperative Sinus Endoscopy (POSE) instrument is a specific tool to endoscopically assess the sinus cavities of patients who have undergone endoscopic sinus surgery.&#xD;
Each POSE score has a minimum of 0 and a maximum of 16, with a higher score indicating a worse outcome.&#xD;
Here, the Left and Right POSE scores are summed and the difference between baseline and the 14 day after treatment is reported.&#xD;
The change in bilateral POSE score can in principle be -32 to +32, with increased scores indicating worse outcome and negative scores indicating improvement over the treatment period.</description>
        <time_frame>Baseline and 14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bilateral Endoscopy Findings Using POSE Score</title>
          <description>The Perioperative Sinus Endoscopy (POSE) instrument is a specific tool to endoscopically assess the sinus cavities of patients who have undergone endoscopic sinus surgery.&#xD;
Each POSE score has a minimum of 0 and a maximum of 16, with a higher score indicating a worse outcome.&#xD;
Here, the Left and Right POSE scores are summed and the difference between baseline and the 14 day after treatment is reported.&#xD;
The change in bilateral POSE score can in principle be -32 to +32, with increased scores indicating worse outcome and negative scores indicating improvement over the treatment period.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.889" spread="5.442"/>
                    <measurement group_id="O2" value="-4.545" spread="2.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming that the non-inferiority limit of topical therapy is 20% of that for oral therapy.</non_inferiority_desc>
            <p_value>0.390</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-treatment Culture Negativity</title>
        <description>Post-treatment culture negativity, defined as less than 1+ growth of organisms. A subject is counted '1' if both nares are free of bacterial growth, and '0' if growth is 1+ of more</description>
        <time_frame>14 days after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-treatment Culture Negativity</title>
          <description>Post-treatment culture negativity, defined as less than 1+ growth of organisms. A subject is counted '1' if both nares are free of bacterial growth, and '0' if growth is 1+ of more</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming that the non-inferiority limit of topical therapy is 20% of that for oral therapy.</non_inferiority_desc>
            <p_value>0.036</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the Total Bacterial Community</title>
        <description>The bacterial community was determined using a 16S rRNA quantitative PCR processed using Quantitative Insights into Microbial Ecology (QIIME) software, version 1.8 to yield the number of operational taxonomic units in each subject sample. The count has a minimum of zero with an increasing score indicating a larger number of distinct bacterial species.</description>
        <time_frame>Baseline and 14 days after treatment</time_frame>
        <population>Data was only collected on the first consecutive 8 randomized participants and had equal numbers in each group</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
            <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
          <group group_id="O2">
            <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
            <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Total Bacterial Community</title>
          <description>The bacterial community was determined using a 16S rRNA quantitative PCR processed using Quantitative Insights into Microbial Ecology (QIIME) software, version 1.8 to yield the number of operational taxonomic units in each subject sample. The count has a minimum of zero with an increasing score indicating a larger number of distinct bacterial species.</description>
          <population>Data was only collected on the first consecutive 8 randomized participants and had equal numbers in each group</population>
          <units>operational taxonomic units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.40" spread="9.530"/>
                    <measurement group_id="O2" value="6.700" spread="7.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Placebo With Nebulized Intranasal Levofloxacin</title>
          <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
        </group>
        <group group_id="E2">
          <title>Oral Antibiotics With Nebulized Intranasal Placebo</title>
          <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.&#xD;
oral levofloxacin&#xD;
nebulized levofloxacin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>bad taste</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Program Manager</name_or_title>
      <organization>UR Medicine Otolaryngology</organization>
      <phone>5852751186</phone>
      <email>paul_allen@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

